These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 9727201

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF.
    Cancer Res; 1997 Dec 01; 57(23):5399-405. PubMed ID: 9393766
    [Abstract] [Full Text] [Related]

  • 3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Dec 01; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 4. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L.
    Oncogene; 1995 Dec 07; 11(11):2419-27. PubMed ID: 8570194
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 2001 Feb 15; 61(4):1426-31. PubMed ID: 11245446
    [Abstract] [Full Text] [Related]

  • 7. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
    Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH.
    Science; 1995 Jan 20; 267(5196):381-3. PubMed ID: 7824936
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN.
    J Clin Endocrinol Metab; 1996 Jul 20; 81(7):2711-8. PubMed ID: 8675600
    [Abstract] [Full Text] [Related]

  • 12. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N, Murakami H, Iwashita T, Takahashi M.
    J Biol Chem; 1996 Jul 26; 271(30):17644-9. PubMed ID: 8663426
    [Abstract] [Full Text] [Related]

  • 13. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
    Cosma MP, Panariello L, Quadro L, Dathan NA, Fattoruso O, Colantuoni V.
    Biochem J; 1996 Mar 01; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
    [Abstract] [Full Text] [Related]

  • 14. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M.
    Biochem Biophys Res Commun; 1997 Aug 28; 237(3):747-51. PubMed ID: 9299438
    [Abstract] [Full Text] [Related]

  • 15. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
    Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, Murakumo Y, Murakami H, Sugiura H, Iwata H, Ishiguro N, Takahashi M.
    Am J Pathol; 2002 Jul 28; 161(1):249-56. PubMed ID: 12107109
    [Abstract] [Full Text] [Related]

  • 16. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S.
    J Endocrinol Invest; 1998 Jun 28; 21(6):358-64. PubMed ID: 9699127
    [Abstract] [Full Text] [Related]

  • 17. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM, van der Luijt RB, Lips CJ.
    Ned Tijdschr Geneeskd; 2001 Nov 17; 145(46):2217-21. PubMed ID: 11757244
    [Abstract] [Full Text] [Related]

  • 18. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M, Jackson CE, Feldman GL.
    Hum Mutat; 1996 Nov 17; 8(1):64-70. PubMed ID: 8807338
    [Abstract] [Full Text] [Related]

  • 19. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I, Vigano E, Alberti L, Borrello MG, Pasini B, Greco A, Mondellini P, Smith DP, Ponder BA, Romeo G, Pierotti MA.
    Oncogene; 1998 May 07; 16(18):2295-301. PubMed ID: 9620546
    [Abstract] [Full Text] [Related]

  • 20. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M.
    Cancer Res; 2000 Sep 15; 60(18):5254-60. PubMed ID: 11016655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.